TSTickerStar
Company alerts/SION
SION company alerts

SION updates worth following

TickerStar monitors official filings, investor releases, earnings, and call updates for SION. Subscribe to SION alerts to receive concise, source-linked alerts when TickerStar detects a meaningful company update.

Official-source feed

Recent SION alert previews

TickerStar filters routine noise and surfaces investor-relevant filings, releases, earnings, and call updates.

EarningsOfficial company source

Sionna Therapeutics Reports Q3 2026 Financial Results; Net Loss of $32.4M

Sionna Therapeutics reported a Q3 2026 net loss of $32.4 million, or $(0.72) per share, compared to a net loss of $20.3 million, or $(0.46) per share, in Q3 2025. Research and development expenses increased to $22.0 million from $16.0 million year-over-year, while general and administrative expenses rose to $12.8 million from $7.8 million. The company ended the quarter with $249.8 million in cash and cash equivalents, which it expects to fund operations into the second half of 2029.

Read source-backed brief
SEC filingSEC filing

SION 10-Q filed 2026-11-10 | Key takeaways

SION filed its 10-Q; the most relevant disclosure change is added Restructuring plan: In September 2026, the board approved a restructuring plan including a 46% workforce reduction following the failure of the PreciSION CF Phase 2a trial for SION-719 as an add-on to Trikafta, with estimated aggregate restructuring charges of $6.4 million and $4.

Read source-backed brief